The Phase 3 lipodystrophy trials Tesamorelins approval rests on two Phase 3 double-blind, placebo-controlled randomized trials (plus their pooled analyses) in patients with HIV-associated lipodystrophy
For a 100 mcg dose, draw 0.05 mL (5 units on a standard U-100 insulin syringe)
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled Phase 3 trials with safety extension data
If indicated, they may use lab testing and structured endocrine evaluation to interpret results in context
GHRP Pathway (Ipamorelin) Ipamorelin selectively stimulates the ghrelin receptor to release growth hormone without raising cortisol, prolactin, or hunger its key clinical advantage over older GHRPs
The combination is used in research examining the downstream effects of simultaneous GHRH receptor and growth hormone secretagogue receptor activation in cell-based assays
